INTERVIEW: Cambridge Cognition Leveraging its new COO

Cambridge Cognition Holdings plc (LON: COG) new COO Matthew Stork joins DirectorsTalk to talk about his move to the company. Matthew provides us with detail around his career, explains why he joined COG, how his past experience will be leveraged in his new role, how he has found the business so far and initial thoughts on growth drivers for the business.

Cambridge Cognition is a leading neuroscience technology company optimising the assessment of cognition for better brain health with scientifically validated digital health solutions. Its software enables gold standard research and efficient clinical trials, accelerating safe and effective treatment development and helping to improve patient outcomes in conditions affecting brain health.

For over 30 years, their technology has been at the forefront of scientific discovery, delivering value to research institutions, healthcare providers and pharmaceutical and biotechnology companies worldwide. From digital health tools to mobile applications for drug development, they provide best in class, interactive and innovative digital cognitive assessment technologies that capture meaningful, reliable data anytime, anywhere.

You might also enjoy reading  Cambridge Cognition excellent order book, healthy pipeline and further opportunity (VIDEO)
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Cambridge Cognition Holdings Plc
INTERVIEW: Cambridge Cognition Leveraging its new COO

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions